164 related articles for article (PubMed ID: 11473078)
21. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.
Inzucchi SE; Maggs DG; Spollett GR; Page SL; Rife FS; Walton V; Shulman GI
N Engl J Med; 1998 Mar; 338(13):867-72. PubMed ID: 9516221
[TBL] [Abstract][Full Text] [Related]
23. Increase of lipoprotein (a) with troglitazone.
Matsumoto K; Miyake S; Yano M; Ueki Y; Tominaga Y
Lancet; 1997 Dec; 350(9093):1748-9. PubMed ID: 9413470
[No Abstract] [Full Text] [Related]
24. Recent advances in the pharmacologic management of diabetes mellitus.
Carlton FB
Emerg Med Clin North Am; 2000 Nov; 18(4):745-53. PubMed ID: 11130936
[TBL] [Abstract][Full Text] [Related]
25. [Troglitazone].
Yamanouchi T
Nihon Rinsho; 2000 Feb; 58(2):389-94. PubMed ID: 10707563
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological regulation of blood glucose levels in non-insulin-dependent diabetes mellitus.
Bressler R; Johnson DG
Arch Intern Med; 1997 Apr; 157(8):836-48. PubMed ID: 9129543
[TBL] [Abstract][Full Text] [Related]
27. Seeking sweet relief for diabetes.
Dove A
Nat Biotechnol; 2002 Oct; 20(10):977-81. PubMed ID: 12355109
[No Abstract] [Full Text] [Related]
28. A miracle of salamization: positive divided by two equals negative.
Iwamoto Y
Diabet Med; 1997 Nov; 14(11):994. PubMed ID: 9400931
[No Abstract] [Full Text] [Related]
29. New oral therapies for type 2 diabetes.
Purnell JQ; Hirsch IB
Am Fam Physician; 1997 Nov; 56(7):1835-42. PubMed ID: 9371013
[TBL] [Abstract][Full Text] [Related]
30. Diabetes mellitus. Medication update.
Slagle M
South Med J; 2002 Jan; 95(1):50-5. PubMed ID: 11827245
[No Abstract] [Full Text] [Related]
31. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.
Yu JG; Kruszynska YT; Mulford MI; Olefsky JM
Diabetes; 1999 Dec; 48(12):2414-21. PubMed ID: 10580431
[TBL] [Abstract][Full Text] [Related]
32. Effect of combination therapy of troglitazone and sulphonylureas in patients with Type 2 diabetes who were poorly controlled by sulphonylurea therapy alone.
Iwamoto Y; Kosaka K; Kuzuya T; Akanuma Y; Shigeta Y; Kaneko T
Diabet Med; 1996 Apr; 13(4):365-70. PubMed ID: 9162613
[TBL] [Abstract][Full Text] [Related]
33. Repaglinide in combination therapy.
Moses R
Diabetes Nutr Metab; 2002 Dec; 15(6 Suppl):33-8. PubMed ID: 12702006
[TBL] [Abstract][Full Text] [Related]
34. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.
Ferrannini E; DeFronzo RA
Eur Heart J; 2015 Sep; 36(34):2288-96. PubMed ID: 26063450
[TBL] [Abstract][Full Text] [Related]
35. Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy--a randomized controlled trial.
Katoh S; Hata S; Matsushima M; Ikemoto S; Inoue Y; Yokoyama J; Tajima N
Metabolism; 2001 Apr; 50(4):414-7. PubMed ID: 11288035
[TBL] [Abstract][Full Text] [Related]
36. Oral agents in managing diabetes mellitus in children and adolescents.
Jacobson-Dickman E; Levitsky L
Pediatr Clin North Am; 2005 Dec; 52(6):1689-703. PubMed ID: 16301089
[TBL] [Abstract][Full Text] [Related]
37. Oral combination therapy in primary care.
Kalra S; Gupta Y
J Pak Med Assoc; 2015 May; 65(5):574-5. PubMed ID: 26028398
[TBL] [Abstract][Full Text] [Related]
38. Oral agents in the management of type 2 diabetes mellitus.
Luna B; Feinglos MN
Am Fam Physician; 2001 May; 63(9):1747-56. PubMed ID: 11352285
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological treatment of type 2 diabetes.
Hermans MP; Buysschaert M
Acta Clin Belg; 2004; 59(2):59-66. PubMed ID: 15224468
[No Abstract] [Full Text] [Related]
40. Troglitazone in type II diabetes mellitus.
Sparano N; Seaton TL
Pharmacotherapy; 1998; 18(3):539-48. PubMed ID: 9620105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]